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ABSTRACT 
The effective surf ace area of a parenteral drug in 
suspension, that which is exposed to body fluids a~ the 
injection site, is a major determinant of its in vivo 
absorption rate. Precise methods o f determining the 
effective surface area without disturbing the in vivo 
system have not been developed . 
A method to estimate the effective surf ace area of 
a subcutane ously injected suspension based on the urinary 
excretion of drug from solid disk implants of known sur-
face area is presented. Standard curves for the mean 
surf ace area of from two to four subcutaneously implanted 
cylindrical disks of pure sulfadiazine versus cumulat ive 
urinary sulf adiazine excretion to 48 hours were developed 
for three test animals . By applying the urinary excretion 
data obtained following the subcutaneous injection of an 
aqueous suspension of sulfadiazine to the appropriate stand-
ard curve for area, a preliminary estimate of the apparent 
or effective in vivo surface area for the suspension formu -
lation was obtained. 
Improvements i n the experimental methodology which 
would control certain biopharmaceutical factors related to 
parenteral drug ab sorption from subcutaneous sites, and 
increase the statistical significance of the surf ace area 
estimate are suggested. 
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I. INTRODUCTION 
Drug implants have been widely used in cancer, endo-
crine, nutrition, chronic toxicity and other studies where 
prolonged drug action is being investigated. The clinical 
use of solid implants is not without disadvantage , how-
ever. A surgical proce dure is required for dosage ad-
ministration or removal, which is usually less convenient 
to the physician and patient than an injection at the same 
site (1). Cosmetically, the suspension is unnoticed, 
whereas the solid dose form would be more likely to be 
noticed and would therefore be less acceptable. Parenteral 
dose forms are thus usually designed as suspensions rather 
than implants when prolonged action is desired. 
The purpose of this project was to develop a prelim-
inary method of determining the apparent or effective sur-
face area of a subcutaneously injected suspension in vivo. 
While there is presently no published method to determine 
the effective surface area of a parenteral drug in suspen-
sion at the site of injection, the mathematical relation-
ships (i.e., models, equations, rate constants and analog 
computer techniques) dealing with the absorption of certain 
solid implanted drugs of known geometric design have been 
investigated by Ballard and others (2-6). The application 
of certa in specifically related principles derived from 
i( 
' ,. 
! 
these studies applied to systems of pure · drug in aqueous 
suspension would be an extension of the class ical work 
on the physical and biological properties of injectable 
procaine penicillin G sus pen s i ons published by Ober et al . 
(7) in 1958. 
The accepted assumptions unde rlying the processes 
involved ·with drug absorption from the implantation site 
are: 1) that the absorption rate is in part proportional 
to the effective solid surface area expos e d to the sur-
rounding tissues and in part due to the intrinsi c physi -
cal properties of the drug, i.e., solubility, pKa , dif-
fusion layer pH and diffusion coefficient ( 2- 4 ), 2) tha~ 
the absorption or disappe arance of drug from a solid 
implant or parenteral depot mimics a zero-order process 
which is dissolution rat e limited, ( i.e ., whe~e the rate -
determining step is the dissolution of drug from the so~ id 
form) (8,9); 3) that the effective or apparent surface 
area of a depot whose geonetry is ill-defined is less 
than the total true surf ace area of all the particles 
making up the suspension as compared to the . a rea of all 
the partic les as measured in vitro by gas adsorption 
techniques ( lO) ;and 4) that the amount of drug and meta -
bolite excreted over time, in this case of sulfadiazine 
and its acetylated metabolite, is directly proport i onal 
to the amount absorbed ( 11 ). 
2 
( 
( 
If a drug is formulated into a compressed pellet 
of known geometric shape and dimension, which can be 
implanted and then removed before it is completely ab-
sorbed , the absorption rate can be estimated if certain 
quantitative information ( e .g., changes in pellet di-
mensions with respect to time ) is known. Accordingly, 
for a disk shaped implant , the weight, W, at any time 
following implantation (t) is (3): 
W = ~ CD0 -kt) 2 CH0 -kt) 4 ( Eq. 1) 
Where~= the apparent density, D0 is the initial diam-
eter of the disk, H0 its initial height and k the ab-
-1 
sorption constant having units of length X time . 
The area, A, of a disk at any time after implanta-
tion is ( 12): 
A= -f- (D0 -kt) 2 +~CD0-kt)(H0 -kt) ( Eq. 2) 
In both these equations it is assumed that the shape of 
the i mplant is not distorted during the implantation 
0 0 time, and that D and H are both~ kt. 
The absorption constant, k, for a geometrically de-
fined drug in pellet form at a particular absorption site 
in a given animal species can be determined using equation 
1 if the pellet dimens ions, density, initial and final 
weights, and implantation time are known. The absorption 
constant can then be used to aid in determining the pro-
bable absorption rates of other geometric forms, e.g., a 
3 
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sphere, of the same drug under similar conditions. 
One of the problems encountered in developing and 
evaluating test suspension formulations is that, upon in-
jecting the dose, there is no way to predict the geometric 
shape of the drug depot in c ontact with the body fluids 
at the injection site. Once the vehicle has migrated 
from the suspension in situ, the suspended injection re-
sembles the geometrically defined pellet with regard to 
all characteristics except shape. The shape of the im-
planted or injected suspension could theoretically vary 
from a flat or very thin sheet (high area/volume ratio) 
at one extreme, to a perfect sphere (minimum area/volume 
ratio) at the other . In practice, the actual shape is 
determined by such fact ors as the injection technique, 
dose formulation and the site of implantation , and is 
within these two extremes. 
The "effective" surface area, that which is immedi-
ately exposed to the action of circulating biological 
fluids, is smaller Than the true area of the sum total 
of all the drug particles in suspension. This effective 
area would be extremely difficult to determine in vivo 
without mechanically qisturbing the system. Thus, one 
cannot use the mathematical equations presented previous-
ly to predict the suspension weight or area at any time 
after implantation because the exact shape of the depot 
4 
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at the site is not known at any given time after the 
injection. Since the net absorption rate is presumed 
to be directly proportional to the effective area, 
which cannot be determined with certainty , absorption 
rate predictions cannot be made accurately. If the 
effective or apparent surface area of the suspension 
depot could be estimated, absorption rates for different 
formulations of the same drug in suspension would then 
allow the product formulator to select the most appro-
priate formulation with the desired characteristics. 
In this study, an in vivo system of implanted 
drug in aqueous suspension was studied in order to 
develop a correlation between a physical property 
(effectiv e surface area) and its biological parameter 
(absorption and urinary excretion) in the same test 
animal. 
Accordingly, two, three and four solid cylindrical 
disks of pure sulf adiazine of known surf ace area and 
weight were implanted on separate occasions and corre-
lated with the amount of drug and metabolite excreted 
over time in the urine. Ballard has shown (5) that if 
the cumulative amount of drug excreted in the urine 
after implantation is plotted against time , a line with 
progressively decreasing slope results , indicating that 
the excretion rate diminishes with time. This decrease 
5 
in rate should be associated with a reduced Jel ~et 
( sur fac e area. The absorption rate of v a r ious n~~~e~s 
o f implant e d pellets per unit time c an be dete~=ined by 
removing the pellets and weighing them. 
unchanged sulfadiazine and its metabolites ~e~e ~easured 
according to a colorimetric assay procedure deve:oped by 
Bratton and Marshall (13 ). Since the ab s orntio~ ra~e of 
the implants is assume d to be proportional to ...... \.... - r-L1!e e:rec-
ti~e surface area exposed , a plot of the ~ea~ s~r~ace 
area of each trial of pellets versus the tota l a~ou~t 
of drug and metabolite excreted in 48 hours ~os~ pe : let 
implantation should result in a linear relation~~ ip . 'lhis 
graph is, in effect, a standard curve for a??2~en~ or 
effective surface area. Following this proced~~e, 2n 
aqueous suspension of sulfadiazine of k nown ~ei~~t , ~hose 
estimated surf ace area is between two a n d four ~ellets on 
the standard curve , was implanted subcut aneously . The 
cumulative excretion of the drug and metabolite ~as 
followed until the implanted dose was c ompletelj a~sorbed 
and excreted . The value for the cumulative amo~nt of drug 
excreted 48 hours after implantation of the s· s:ie:llsion can 
then be appl i ed to the least squares regressi~n li_ e on the 
standard curve for area generated with the disk . 7hus, 
the solid-equivalent or apparent mean surface a~ea ~or the 
drug in suspension should be determined for the snecif ic 
formulation in the test animal observed . 
( 6 
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II. MATERIALS AND METHODS 
Thin cylindrical disks of drug grade sulfadiazine1 
without further purification were prepared . About 50 mg 
of the powder was compressed at 7158 kg/cm 2 on a Carver 
2 Laboratory press modified to allow the use of standard 
tablet ing machine punches and dies. The prepared disks 
had a mean diameter of 0.6369 cm (0.6350 c m to 0.6398 cm) 
and a mean height of 0 . 1123 cm (0.0940 c m to 0 . 1341 cm) 
when measured by a micrometer. The disks were weighed 
on a standard analytical balance 3 and were between 41 . 14 
mg and 56.82 mg (mean - 48 . 93 mg) in weight. Thus, the 
disks had a calculated mean density of 1 . 37 gm/cm3 prior 
to implantation. 
The sulf adiazine powder used to prepare the solid 
disks was also used without modification · to prepare the 
aqueous suspension for subcutaneous implantation. An 
independent microscopic analysis was performed to deter-
mine the average particle surface area and specific sur-
4 face of the powder (See Appendix). The apparent 
1 . Pfaltz and Bauer , Inc ., · 126-02 Northern Blvd., Flushing, 
New York 11368. 
2 . Car1er Laboratory Press Model C, Fred S. Carver, Inc., 
subsid iary of Sterling, Inc., Fountain Blvd., Menomonee 
Falls, Wisconsin 53057 
3 . Type H-16, Metler Instrument Corp., Hightstown, New 
Jersey . 
4. Courtesy, Dr. T. J. Rockett, Associate Professor of 
Materials and Chemical Engineering, College of Engineering, 
University of Rhode Island, Kingston , Rhode Island 02881 
l e 
powder density estimated independently by pycnometer 
3 
was 1.43 gm/ cm . 
Quantities of twenty percent ( w/w ) sulfadiazine 
suspension were prepared as needed by adding 10 . 0 ml of 
n ormal saline by pipette to 2.5 gm of sulfadiazine powder 
accurate l y weighed. No binders , diluents, excipients or 
lubricants were added . The resultant suspension was 
shake n on a Burrell shaker 5 at maximum rotation (10 
degrees ) for one hour. 
On separate occasions, two, three, and four s olid 
disks and a known weight and volume of 20% ( w/ w) aqueous 
suspension of sulf adiazine were implanted into each of 
three male Sprague - Dawley rats, A-379 gm , B-37 5 gm, and 
C-359 gm (mean weight 371 gm ) according to the method of 
Ballard and Nelson (2). During the experiments the animals 
were fed standard l aboratory chow once daily and water 
ad libitum. They were placed in separate stainless steel 
cages from which the urine samples and cage washings could 
easily b e collected . 
Immediately prior to a sulfadiazine disk i~plantation 
trial, the animal was lightly anesthetized with ether and 
a ventral midline incision of suitable length was made in 
the abdominal skin. The subcutaneous tissue surrounding 
5. Burrell Corporation , 2223 Fifth Avenue , Pittsburgh, PA 
15219. 
8 
( 
the incision was teased apart to provide from two to four 
site s for the implantation of the disks as appropriate. 
Following this, the disks were implanted in two, three, 
or four corner sites, the implantation time was noted, 
an d the incision wa s closed by suturing . 
After the 48 hours urine sample collection, the animal 
was reanesthetized, the sutures were cut and the disks 
were located manually and removed by palpation without 
the aid of forceps. The time of disk removal was noted, 
the implantation site was resutured and the site was not 
reused. The mean implantation time for the nine disk 
implant trials was 48 . 31 (range 47 . 98 - 48 . 63) hours . 
The extracted disks were placed briefly on a filter 
paper which had been previously wetted with 3% (v/v) 
hydrogen peroxide so l ution in order to remove any closely 
adhering tissue . The disks were then allowed to air dry 
for 24-48 hours prior to measurement of their final 
weights and dimensions . 
The suspensions were deposited utilizing a similar 
procedure. Following light ether anesthesia, a subcutaneous 
injection of 0.125 ml of the suspension depot was made in 
the midventral abdominal wall using a previously tared 
glass syringe 6 fitted with a 21 gauge 38 mm needle 6 . The 
6. Becton Dickinson and Company, Box 183, Rutherford, New 
Jersey 07070 . 
9 
time of implanting the depot was noted. To estimate 
the amount of suspension deposited , the following 
gravimetric technique was used. The tared sy~inge 
containing a quantity of sulfadiazine suspension was 
placed on its side ( in order to assure that suspended 
solid drug that settled would do so on the length o f 
the syringe wall ) and weighed. An approxi~ate 0.125 
ml sample was quickly injected first into the animal; 
the syringe was reweighed and a second 0 . 125 ml of the 
sample was injected into a volumetric flask . The syringe 
was once again weighed. 
Thus , the weight of suspension inj e cted into the 
test animal could be determined by the difference be -
tween the initial weighing of the syringe and total 
contents minus the s e cond weighing. The third we ighing 
determined the weight of an equivalent volume of sus-
pension delivered to the flask which was later analyzed 
to provide an additional estimate of the amount of 
sulfadiazine injected into the test animal . 
In order to assess sulfadiazine excretion, urine 
samples with distilled water cage washings were collected 
at approximately 12 hour intervals for 96 hours after 
separate implantations of the two , three , and fou r disks . 
Samples were collected at approximately 24 hour intervals 
for 240 hours following subcutaneous injection of the 
10 
I 
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suspension. Because the sulf adiazine suspension remaining 
to be excreted 48 hours after injection could not be 
easily recovered from the site, it was necessary to collect 
urine samples for 10 days following subcutaneous adminis-
tration. During both the disk and suspension experiments 
the animals were induced to void at the appropriate times 
by introducing 0.5 ml of ether into the cages. Repe tition 
produced voiding if the initial attempt was unsuccessful. 
Enough distilled water was added to each 12 or 24 
hour sample with cage rinsings to bring the final volume 
to 400 ml which was then well-stirred. A 90-120 ml portion 
of this dilution was frozen (-17°) for future assay. 
Urine was assayed for total (total = free + acetylated) 
sulf adiazine according to the colorimetric assay procedure 
of Bratton and Marshall (13). Reagents for the determin-
ation of sulfadiazine in the urine included 4N hydr ochloric 
acid 7 , 0.1% sodium nitrite 8 which was freshly prepare d 
daily, 0.5% arrunonium _sulfamate 8 , and 0.1% N-(1-naphthyl)-
ethylenediamine dihydrochloride 8 which was stored in a 
dark bottle in the refrigerator and prepared each week. 
In this assay, protein-free urine is treated with 
nitrous acid to diazotize free sulfonamide. Excess nitrous 
7. Allied Chemical Corp., Industrial Chemical Div., P.O. 
Box 6, Solvay, New York 13209. 
8. Fisher Scientific Co., 711 Forbes Avenue, Pittsburgh, 
Pennsylvania 15219. 
11 
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acid is destroyed with ammonium sulfamate and the diazo-
tized sulfonamide is coupled with N-naphthylethylenediamine 
to form a stable red-violet color. The absorbance is known 
to follow Beer's Law and is compared with stock standard 
solutions of sulfadiazine at 545 nm using a Spectronic 20 
colorimeter9 fitted with a constant voltage transforcler9 . 
In this experiment previously frozen samples of urine, 
which had been diluted to 400 ml, are thawed and further 
diluted with distilled water as required. To ten milli-
liter portions of the dilution to be assayed is added 
0.5 ml of 4 N hydrochloric acid. For determining total 
sulfadiazine (free drug plus its acetylated metabolite), 
the acidified sample is then placed in a boiling water 
bath for one hour. One milliliter of 0.1% sodium nitrite 
is added to diazotize the primary amine. After three 
minutes, 1 ml of 0.5% ammonium sulfamate is added to 
destroy any excess nitrous acid present. After two minutes, 
1 ml of 0.1% N-(1-naphthyl)-ethylenediamine dihydrochloride 
is then read at 545 nm against a distilled water blank. 
Blank (drug-free) urine collected prior to drug 
implantation or injection is treated and analyzed in the 
same manner as samples containing sulfadiazine. Corrected 
values for the absorbance of each sample are used to 
9. Bausch & Lomb, Inc., Analytical Systems Division, 
820 Linden Avenue, Rochester, New York 14625 . 
12 
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calculate the cumulative amounts of total sulfadiazine 
excreted in each 24 hour period. 
13 
III. RESULTS 
( 
Tables I and II give the measured he ight, diameter 
and weight of each of the sulf adiazine disks before and 
after implantation. From these data, t he volume, area, 
and density were calculated . These values are also in-
eluded in Tables I and II. 
Tables III, IV, and V provide urinary excretion data 
for to·tal sulfadiazine for rats A, B and C, respectively, 
at various time periods. 
From the disk implant and urinary excretion data 
obtained, the mean absorption rates per mean area, RIA, 
and absorption constant, k, can be calculated for each 
implant trial. These values are given in Tables VI, VII , 
. ( 
I 
and VIII . 
The values found by assay for the amount of total 
sulfonamide excreted in 48 hours versus the mean sur~ace 
area of the implanted disks are given and also plotted, 
and the appropriate least squares regression line has been 
constructed, for each animal in Figures 1, 2, and 3. 
The extrapolated mean surf ace area of the suspension 
(Tables VI, VII and VIII) was found by using the equation 
of the least squares line and the weight of total sulfa-
diazine assayed at 48 hours following suspension implanta-
tion. 
TABLE I 
( 
Data on Sulf adiazine Disks Before Implantation 
Pellet Height Diameter Wei ght Volu~e Density Area 
Number (cm) (cm) ( mg) (cm ) ( gm/cm3 ) (cm2 ) 
1. 0.1102 0.6372 47.76 0.03514 1. 35 9 0.8584 
2. 1190 6392 52.89 3819 1.385 8076 
3. 1290 6383 56.82 4128 1. 37 7 8987 
4. 1263 6366 55.79 4020 1. 388 8892 
5. 1324 6350 55.30 4193 1.319 8975 
6. 1066 63 65 47.32 3392 1. 395 8495 
7. 1098 6371 48.10 3500 1. 374 8573 
8. 1019 6373 44.26 3251 1. 362 842 
9 . 1041 6371 46.12 3319 1. 39 8450 
10. 1275 6 373 55.77 4067 1. 371 8933 
11. 1251 6362 55.10 3977 1. 386 8858 
12. 0979 6 360 41. 71 311 1.341 831 
( 13. 0985 6362 44.32 3131 1. 415 8327 
14. 1042 6361 44.19 3113 1. 335 8438 
15. 1270 6387 54.30 4069 1.334 8956 
16. 1183 6360 52.54 3758 1. 39 8 8718 
17. 0988 6370 41. 61 3149 1.322 8351 
18. 1115 6372 48.28 3556 1. 35 8 8610 
19. 1341 6350 58.19 4247 1.371 9009 
2 0. 1158 6363 50.36 3682 1. 36 8 8675 
21. 0982 6390 42.77 3149 1. 35 8 8385 
22. 0940 6398 41.14 3022 1.361 8319 
23. 0973 6360 41. 29 3091 1.336 8298 
24. 1215 6350 54.04 3848 1. 404 8758 
25. 1145 6355 50.43 3632 1. 3 89 863 
26. 1029 6393 44.63 3303 1. 351 8487 
27. 1052 6365 46.10 3347 1. 377 8467 
Mean 0.1123 0.6369 48.93 0.0357 1. 36 8 0.8592 
15 
TAB LE II 
( 
Data on Sulf adiazine Disks ·After Implantation 
Pellet Height Diameter Weight Volume Density Area 
Number (cm) (cm) ( mg ) (cm3) ( gm/cu3 ) (cm2 ) 
1. 0.10 23 0.5320 42.15 0.03209 1. 313 0.8305 
2 . 1131 6355 47.12 3587 1 . 313 8602 
3. 1190 6279 48.26 3685 1. 31 8540 
4. 1179 6280 47.40 3652 1. 298 8521 
5 . 1250 6291 50.35 3885 1.2 96 86 87 
6. 1040 6246 42.69 3187 l. 34 8169 
7. 1062 6305 45.17 3316 1 .3 62 8348 
8. 0857 6183 33.65 2573 1 .3 08 767 
9. 0816 6199 35.94 24 63 1.459 762 6 
10. 1216 6311 49.16 3804 1. 2 92 8667 
11. 1181 6343 47.55 3732 1 .2 74 8673 
12. 0858 6255 32.57 2637 1. 2 35 7832 
! ( 13. 0932 6280 
I 
38.91 2 88.7 l. 348 8034 
14. 0947 6277 37.64 2931 1 . 284 8057 
15. 1178 6320 47.61 3696 1 .2 88 8613 
16. 1100 6301 46.86 3430 1 . 366 8414 
17. 0893 6298 35.57 2782 1. 279 7997 
18. 1013 6310 42.41 3168 1.339 82G2 
19. 1288 6323 55.07 4044 1.362 8839 
20. 1118 6322 45.07 351 1. 284 8499 
21. 0905 62 94 35.88 2816 1. 274 8012 
22. 0 896 6281 35.08 2776 1.264 7965 
23. 0850 6311 35.12 2659 1. 321 7942 
24. 1146 6317 48.44 3592 l. 349 8543 
25. 1060 6317 44.62 3221 1.343 8 3 72 
26. 0961 6287 38.84 2983 1 . 302 8107 
27. 1002 6317 41. 09 314 1. 308 8257 
Mean 0.1040 0.6293 42.60 0.03236 1. 315 0.828 
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TABLE III 
( Cumulative Total Sulf adiaziile Excretion 
in Mg After Implantation 
Rat-A 
Time (hr.) Two Three Four Sus12ension 
Pellets Pellets Pellets 
0-24 3.81 8.84 11. 65 1. 91 
24-48 7.02 12.13 22.38 5.59 
48-72 9.5 14.13 26.51 6.31 
72-9 6 9.86 15.00 27.39 6.84 
96-120 8.08 
120-144 8.31 
144-168 8.58 
168-192 8.81 
192-216 9.02 
216-240 
Total 9.86 15.00 27.39 9.02 
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TABLE IV 
( Cumulative Total Sulfadiazine Excretion 
in Mg After Implantation 
Rat - B 
Time (hr . ) Two Three Four SusEension 
Pellets Pellets Pellets 
0- 24 3 . 63 10.27 10 . 95 9 . 64 
24- 48 7 . 5 2 18.01 18 . 96 12 . 43 
48-72 10 . 01 21. 4 7 23.78 13.55 
7 2- 96 11. 44 22 . 3 25 . 32 14 . 19 
9 6 - 120 14 . 61 
1 20 - 144 14 . 61 
1 44 - 168 
168 - 192 
( 1 92 - 216 
216 - 240 
i 
I Total 11 . 44 22 . 3 25 . 32 14 . 61 
I 
, I 
I 
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TABLE v 
( Cumulative Total Sulf adiazine Excretion 
in Mg After Implantation 
Rat-C 
Tir:1e (hr .) Two Three Four SusEension 
Pellets Pellets Pellets 
0-2 4 2 . 58 7. 63 8.2 4 8.59 
24-48 6.40 14.29 17.13 10.77 
48-7 2 6.91 18.30 22.6 11. 57 
72-96 20.4 0 24.13 12.11 
96-1 20 12.39 
12 0-144 12.75 
14 4-168 
16 8-192 
19 2-216 
( 216-240 
Total 6 . 91 20.40 24.13 12.75 
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N 
0 
Dimension or Property 
Height (H) cm 
Diameter (D) cm 
Weight (W) gm 
Estimated Area (A) cm2 
Estimated Volume (V) cm3 
Apparent Initial 
Density (i)) gm/cm3 
Implantation Time (t) hr 
Initial time of Implantation 
Total Weight Lost gm 
(Wi-Wf) 
Wt SDZ Assayed 
R.;J.. x ~f4 
@ 96 hr gm 
gm/hr /cm2 
-1 X time k X 10 length 
R.!"Ate 
k 
Mean Surface Area over 
48 hr/pellet (Ai+Af/2) 
Total Apparent Su_E.face 
Area over 48 hr (A) 
2 
cm 
2 
cm 
-· 
TABLE VI 
Sulfadiazine Implant Data - Rat A 
Mean of Two Pellets Mean of Three Pellets 
(// l, t/2) (113-115) 
Initial Final Initial Final 
.1146 .1077 .1292 .1206 
.6382 .6338 .6366 .6283 
.05033 .04464 .05597 .04867 
.8696 .8454 . 8951 .8583 
.0367 .0340 .0411 .0374 
1. 37 1. 36 
48.37 47.98 
10:22 A.M. 9:46 A.M. 
.01138 .02190 
.00986 .01500 
1. 37 1. 74 
2.02 2.58 
.495 .496 
. 8575 .8767 
1. 72 2.63 
--. 
Mean of Four Pellets Suspension 
(116-119) 
Initial Final 
.1056 .0944 
.6370 .6233 
.04645 .03936 
.8485 . 7953 
.0337 .0288 
1. 38 
48.30 
10:47 A.M. 4:11 P.M. 
.0 2835 
.02739 .00684 
1. 78 
2.61 
.494 
. 8219 
3.29 1. 75 
N 
I-' 
Dimension ot Property 
Height (H) 
Diameter (D) 
Weight (W) 
Estimated Area (A) 
Estimated Volume (V) 
cm 
cm 
gm 
2 
cm 
3 
cm 
Apparent Initial 
Density (,P) gm/cm3 
Implantation Time (t) hr 
Initial time of Implantation 
Total Weight Lost gm 
(Wi-Wf) 
Wt SDZ Assayed 
R.;A. x lo-4 
@ 96 hr gm 
2 gm/hr /cm 
-4 k X 10 length -1 X time 
R/A/(' 
k 
Mean Surface Area over 
48 hr/pellet (Ai+Af /2) 
Total Apparent Surf ace 
Area over 48 hr (A) 
2 
cm 
2 
cm 
..--.. 
TABLE VII 
Sulfadiazine Implant Data - Rat B 
Mean of Two Pellets 
(1110 ' fill ) 
Initial Final 
.1263 .1199 
.6368 .6327 
.05544 .04836 
.8895 .8670 
.0402 .0377 
1. 38 
48.30 
9:33 A.M. 
.01416 
.01144 
1. 67 
2.46 
.492 
.8783 
1. 76 
Mean of Three Pellets 
(f/12-1114) 
Initial Final 
--- ---
.1002 .0912 
.6361 .6271 
.OL13U .03637 
. 8358 .7974 
.0318 .0282 
1. 36 
48.32 
2:17 P.M. 
.02110 
.02230 
1. 78 
2.63 
.498 
.8166 
2.45 
Mean of Four Pellets 
(1115-1118) 
Initial Final 
--
.1139 .1046 
.6372 . 6307 
.04918 .OL1361 
.8659 .8322 
.0363 .0327 
1.35 
48.25 
12:20 P.M. 
.02428 
.02532 
1. 48 
2.21 
.496 
.8491 
3.40 
~ 
Suspension 
2:55 P.M. 
.01419 
2.27 
Dimention or Property 
Height (H) 
Diameter (D) 
Weight (W) 
Estimated Area (A) 
Estimated Volume (V) 
cm 
cm 
gm 
2 
cm 
3 
cm 
Apparent Initial 
Density ('P) 3 gm/cm 
N Implantation Time (t) hr 
N 
Initial time of Implantation 
Total Weight Lost gm 
(Wi-Wf) 
Wt SDZ Assayed 
R/A x 10-Lf 
@ 96 hr gm 
2 gm/hr/cm 
-4 k X 10 length -1 X time 
R/ A/{' 
k 
Mean Surf ace Area over 
48 hr/pellet (Ai+Af/2) 
Total Apparent Surf ace 
Area over 48 hr (A) 
2 
cm 
2 
cm 
...--...._ 
TABLE VIII 
Sulfadiazine Implant Data - Rat C 
Mean of Two Pellets Mean of Three Pellets 
(1119'1120) (1121-1123) 
Initial Final Initial Final 
.1250 .1203 .0965 .0884 
.6357 .6323 .6383 .6295 
.05428 .05007 .04173 .03536 
.884 2 .8669 .8334 . 7971 
.0396 .0378 .0309 .0275 
1. 37 1. 35 
48.63 48.32 
9:46 A.M. 2: 36 P .M. 
.00842 .019 12 
.00691* .0204 
. 989 1. 62 
1. 46 2.41 
. 494 . 498 
.8755 . 8153 
1. 75 2.45 
* Cumulative value @ 72 hrs; no 96 hr sample 
Mean of Four Pellets Suspension 
(1124-1127) 
Initial Final 
--
.1110 .1042 
.6366 .6310 
.04880 .04325 
. 8585 .8319 
. 0353 .0 326 
1. 38 
48.35 
12:45 P.M. 2:55 P.M. 
.02221 
.02413 .01211 
1. 36 
1.99 
.495 
.8452 
3.38 2.27 
3 
A 2 
N 
\,;.) 
,---.._ 
FIGURE 1. STANDARD CURVE FOR MEAN SURFACE AREA FOR RAT A 
... 
• 
No. Pellets 2 .C4') 3(.A.) 4 ( 11!1 ) 
A 1. 72 2.63 3.29 
Mg. total SDZ 7.02 12.13 22.38 
Excreted to 
48 hours 
10 15 
TOTAL SULFADIAZINE EXCRETED TO 48 HOURS (MILLIGRAMS) 
...... 
m = .0968 
b = 1.207 
2 
r = .9228 
t(n-2) 3.445 
SusEension ( ¢) 
1. 75 (est.) 
5.59 
20 
--
3 
'j\ 2J 
N 
~ s 
,...-..._, 
FIGURE 2. STANDARD CURVE FOR MEAL~ SURFACE AREA FOR RAT B 
~ 
'No. Pellets 2 ( 9) 3( ~) 4 (.) 
A 1. 76 2.45 3.40 
Mg . total SDZ 7.52 18.01 18.96 
excreted to 
48 hours 
10 15 
TOTAL SULFADIAZINE EXCRETED TO 48 HOURS (MILLIGRAMS) 
......_ 
A m = .1113 
b = . 8868 
2 
.7356 r = 
t (n-2) = 1. 6683 
Suspension ( ¢-1 
2.27 (est.) 
12.43 
20 
,,--. 
J-
'A 2-i 
N 
V1 5 
.--.. 
....... 
FIGURE 3. STANDARD CURVE FOR MEAN SURFACE AREA FOR RAT C 
II 
... 
m = . 1383 
b = . 7827 
2 
. 885 r = 
/ t(n-2) = 2.7686 
No. Pellets 2 ~.) 3~ ... ) 4( a) Suspensi.on (¢) 
-
A 1. 75 2 .45 3.38 2.27 (es t.) 
Mg. total SDZ 6.4 14.29 17.13 10 . 77 
excreted to 
48 hours 
ro 15 20 
TOTAL SULFADIAZINE EXCRETED TO 48 HOURS (MILLIGRAMS) 
( 
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IV. DISCUSSION 
The quantitative aspects of subcutaneous drug absorp~ 
tion and the physiochemical factors which af f ect this pro -
cess have been reviewed by Schou (14 ) , Ballard (2 , 15 ) , and 
Ritschel ( 16) . The evaluation of parenteral suspended or 
solid implanted dose formulations depends in part upon the 
de t ermination of the surface area of the solid particles 
of the depot exposed to the surrounding tissue and fluids 
once the suspension vehicle has migrated from the injection 
site ( 15 ). The influence of crystalline particle size on 
surf ace area and on drug absorption was demonstrated in 
1 9 55 by Foglia ( 1 7) . He showed that by increasing the 
surface area of parahydroxypropiophenone ( PHP) through a 
particle size reduction from 10 , 000 ~ 3 to 2000 ~3 , pharma-
c o logical activity could be produced in rats in parenteral 
do ses of 0. 05 rag where no activity was demonstrated in doses 
as high as 120 mg using the larger particle size . 
In 1958, Ober and co-workers (7) correlated the rheo-
l ogical and physical properties of intramuscularly injected 
aqueous suspensions of procaine penicillin G with inject -
a b ility and clinical response in rabbits . In addition to 
specifying the optimum ranges for specific surf ace and 
particle size distribution of the antibiotic powder and 
structural breakdown point of the suspension formulation, 
the investigators used a 2% gelatin gel as a model for 
screening test preparations. They also demonstrated the 
( formation of a spherical depot or "thixotropic pellet" at 
the intramuscular injection site. 
Presently, various methods are commonly used to assess 
the absorption rates of drugs from intramuscular and sub-
cutaneous sites. Monitoring of the pharmacological response 
of certain drugs or serum level determinations of drugs and 
their biologically active metabolites are often used in 
this regard. In 1969, Baldridge (18) recommended the assess-
ment of urinary drug and /or metabolite concentrations as a 
simple procedure to assess drug absorption over time. The 
absorption rate of sulf adiazine from pellet implants and 
subcutaneous injections is readily determined via the urinary 
excretion method. The excretion of sulfadiazine and its 
( acetylated metabolite by the rat occurs primarily via the 
urine according to a first order kinetic process. 
A pharmacokinetic model for the absorption, distribution, 
metabolism, and excretion of sulfadiazine in rats has been 
presented by Ballard and Goyan (6): 
Sa----.~Sae 
k 
r k1k2 
Si---~ S---~ Se 
l 
Su----# Sue 
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In this model, Si is the amount of drug in the disk or 
injection at the implantation or injection site, respectively, 
S is the amount o f free drug distributed in body fluids of 
the animal, Se is the cumulative amount of free drug ex-
creted unchanged in the urine, Sa is the amount of acetylated 
drug in the fluids of distribution in the animal, and Sae is 
the cumulative amount of acetylated drug excreted into the 
urine up to any time. Su and Sue are, respectively, the 
amount of sulfadiazine and/or its metaboli te (s) distributed 
to a hypothetical unknown compartment, and the cumula~ive 
amount excreted to any time by a non-urinary route. 
The rate constant, k, is a mean absorption constant 
. -1 having dimensions of length x time . The rate constants, 
k 1 , k 2 and k 3 are first order rate constants for acetylation , 
urinary excretion of acetylated and urinary excretion of free 
-1 drug, respectively , in units of time . The consta nt k 4 is 
the first order constant for the elimination of free drug by 
a route other than the urinary one, or is the formation con-
stant of an undetected metabolite, and k 5 is the first order 
constant for the elimination of that metabolite by some route, 
if appropriate . 
The mean constant, k, for each animal was estimated 
from the following equation by the method of successive 
approximations using data on the initial and final mean 
weights, and initial mean disk heights, diameters, densities , 
28 
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and total implantation time , t (6): 
Si = amount (weight) of drug 
i' = apparent density of implanted disk s 
Do 
= initial (mean) diame t er of disks 
Ho 
= initial (mean) height of disks 
t = implantation time (hrs) 
The mean absorption rate per mean area, RIA, p e r disk, 
was estimated from the following equation: 
(Wi - Wf)lti 
RIA per disk = 
(Ai + Af)l2 
where Wi and Wf are the initial and final mean disk weights 
for each separate implantation trial, ti is the i mplantat ion 
time and Ai and Af are , respective ly, the initial and fi nal 
mean areas of the implanted disks. 
Values for the absorption constants, k, and the mea~ 
absorption ratea per mean surface area , RIA, which were ob-
tained for 2, 3, and 4 implanted disks of sulfad iazine in 
NOTE: For cylindrical disks, the mean absorption rate , RIA, 
absorption constant, k, and pellet density,~, are theoreti-
cally related in ·the following manner: 
RIA 
-.p- = k -2-
Thus, RIAl~lk should equal 0.5. Values close l y a ppr oximating 
0.5 using the abov e equation were calculate d from the appro-
priate data (Tables VI-VIII). 
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rats A, B and C are generally similar to those previously 
reported in studies (2,5) utilizing a siffi ilar experimental 
design. 
As a first approximation, the mean absorption rate of 
a subcutaneous i mplant at any time is considered to be 
proportional to the surf ace area exposed to body fluids 
at the implantation site (2). When the in vivo absorption 
rate of sulf adiazine from implanted disks is approximated 
by urinary excretion of sulfadiazine and its metabolite 
unexpected variations in the results may occur. These 
may depend partly upon the influence of certain biopharma-
ceutical and physiological factors inherent to the model 
and partly to the experimental design. 
The pH of body fluids (i.e., urine and plasma ) is 
known to affect the excretion rate and plasma half-lives 
of drugs which are weak acids and bases. Sulfadiazine, an 
organic weak acid, has a pKa' of 6.28 at 28 c0 (12). 
According to the pH partition hypothesis (19), a large 
port ion of sulfadiazine would exist in the ionized form if 
the urine were previously rendered alkaline ( pg 8) with 
sodium bicarbonate. The urinary excretion rate of sulfa-
diazine would be increased due to a reduction in renal 
tubular reabsorption. In this experiment the nH of the 
urine was not controlled. 
The time of urine sample collections for each separate 
disk and injection trial was dependent upon the time of disk 
30 
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implantation or suspension injection. The time of implanta-
tion and injection varied from 9:33 A.M. to 4:11 P.M. Dettli 
and Spring (20) have shown that urinary pH variations in man 
over a 24 hour period may be of such magnitude as to result 
in significant alterations in urinary su lfonamide excretion 
rate s. It is possible that urine pH variations could have 
affected sulf adiazine excretion rates for different implant 
trials in the present experiment. Consecutive pellet implan-
tation and subcutaneous injection trials should be performed 
and urine samples collected at roughly the same time of day. 
Additionally , the urine pH of each sample should be monitored 
to detect significant variations that might lead to changes 
in drug excretion rates. 
Body movement has been shown to affect the absorption 
of drugs from pellets. Ballard (21) reported a statistically 
significant increase in the absorpLion of procaine penicillin 
G implants from rats subjected to exercise. Theoretically, 
increased body movement can result in increased drug dis-
solution due to a stirring effect. In the present experiment, 
body movement was not controlled. 
At different sample times, voiding may not have been 
complete, and therefore some drug may have remained in the 
bladder. Incomplete bladder emptying at the 48 hour col-
lection of this experiment would have resulted in inappro-
priately low cumulative sulfadiazine excretion. The problem 
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of incomplete voiding is lessened somewhat when data are 
collected over long time intervals (6). Also, in this 
experiment, water was continuously available to the animals. 
Baldridge ( 18) has recommended administering water just prior 
t6 drug dosing and routinely thereafter to maintain urinary 
flow rate and enhance drug excretion . 
Significant migration of the implanted disks occurred 
during the experiment. In a fourth experimental animal, 
during one of the disk implant removal procedures, two 
adjacent disks were discovered to be overlapping. It was 
impossible to determine either the initial time o~ this 
occurrence or the resultant decrease in total i mplant sur-
face area. Hence, a data point on the standard c~rve for 
this animal was unobtainable and , since time did not permit 
repetition of the particular trial, previous data were 
invalidated . 
In a recent report by Kent (22) wherein six ~elman-
dinone acetate pellets of approximately 28 mg were implanted 
subcutaneously in rats, the author utilized separate 
implantation sites for each disk . When more than one pellet 
is to be implanted, it would be advantageous to make separate 
incisions both to facilitate identification and to minimize 
implant migration. 
Since only three data point s were determi ned for the 
surface area versus urinary sulfadiazine excretion plots, 
32 
it was not possible to perform standard statistical analysis 
on the least squares curve obtained. Values for Total sulfa-
diazine excretion in anima.ls B and C for the three and four 
disk trials are very close together considering t~e difference 
in mean implant surface areas exposed (figures 2,3). Un-
fortunately, it cannot be determined whether urin~~y sulfa-
diazine excretion to 48 hours was inappropriately high during 
the trial with three implanted disks, or if excre~ion during 
the trial with four disks was inappropriately low. Urinary 
excretion values would be higher than expected if res idual 
sulf adiazine from the immediately previous imp la~~ation trial 
was present . Had time permitted, a better fit of th~ least 
squares curve could have been obtained if another im~lantation 
trial utilizing a single 50 mg disk of sulfadiazi~e had been 
performed . Additional data points would also be 8btainable 
if disks of other diameters could have been prepa~ed . Various 
combinations of such disks would permit additional data points 
on the standard curve which were intermediate in surface area 
to those obtained by combining single disks of the same di-
mensions. The appropriate number of trials coulc then be 
made until the necessary degree of statistical s~gni=icance 
was attained . 
Another problem area within the experimenta_ nethodology 
occurred with rega rd to the injection of the sulfadiazine 
suspension . While the subcutaneous inj ection was being made 
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into animal A, an unknown volume of suspension leaked from 
the injection site. Thus, while the precise volume and 
weight of suspension injected into animal A could not be 
determined, it was significantly less than the 0.125 ml 
injected into the other two animals. The leaked portion 
was collected from the site on filTer paper for later 
analysis in order to estimate the amount of suspension 
injected, however, a precise detercination could not be 
made. The amount of total sulf adiazine excreted up to 
48 hours following the partial injection of the suspension 
in rat A was considerably less (about 5.6 mg) when compared 
with 12.4 mg and 10.8 mg excreted over the same time interval 
by rats B and C, respectively. This difference was reflected 
in the mean surface area estimates which for rat A ( 1.78 cm 2 ) 
2 2 
was 26% less than for rat B (2.27 cm ) and rat C (2.27 cm ). 
The mean surface area determination for rat A is further 
suspect since it occurs outside the boundaries of the exper-
imental data for rat A used to construct the standard curve 
for surface area. Extrapolation of the mean surface area of 
the suspension injected into animal A is possible only with 
the assumption that the standard curve for rat A is linear 
in the region below the data point corresponding to a cumu-
lative total sulfadiazine excretion of about 7 mg. 
Despite the above factors which theorectically or 
actually affected the urinary excretion of sulfadiazine, 
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values for the cumulative amount of drug eliminated at the 
end of 48 hours provide the best approximation of a standard 
curve for surface area . The majority of the effect on sulfa-
diazine urinary excretion can be related to the surface area 
of the disks or injections exposed to the animal body fluids 
at the site of implantation. 
The results obtained indicate that a preliminary estimate 
of the effective surface area of 0.125 milliliters of the 20% 
w/w sulf adiazine suspension prepared would be about 2 2 cm , 
or an area approximated by from two to three 50 mg cylindrical 
disks of pure sulfadiazine, each with an average surface area 
of 0.86 square centimeter . 
The approximate weight of sulfadiazine suspensio n injected 
into animals A .and B was 96.18 and 92.72 mg , respe ct i ~ely . 
This weight corresponds to 19.23 and 18.54 mg of sul f adiazine 
powder. The surface area per milligram of powder was estimated 
via quantitative microscopy to be 8.933 square centineters per 
milligram (See Appendix). The calculated total initial surface 
area of the powder in aqueous suspension using this nethod is 
8.933 cm2 /mg times the appropriate 
2 
weight of powder injected , 
or 171.78 cm for rat A and 165.61 2 cm for rat B. 
2 
estimated effective surface area value of 2.27 cm 
Thus , the 
determined 
for both animals using the proposed in vivo method is less 
than 2% of the total surface area of the drug crystals in 
suspens ion initially injected as calculated microscopically. 
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V. SUMMARY 
1. Thin cylindrical disks of pure sulfadiazine of known 
surface area and weight were implanted into three test 
animals . Total urinary sulf adiazine excretion was followed 
to assess the absorption rates of the sulfonamide from sub-
cutaneous tissue. 
2. Standard curves for mean disk surface area versus 
cumulative sulfadiazine excretion to 48 hours were prepared. 
A quantity of sulfadaizine in aqueous suspension was then 
injected subcutaneously and its cumulative urinary total 
sulfadiazine excretion to 48 hours used to obtain a pre-
limina ry estimate from the standard curve of the effective 
in vivo surf ace area of the injected suspension in the 
test animal observed . 
3. The reliability of the proposed method to accurately 
estimate the effective mean suspension surf ace area cannot 
be established from the present data. However, the validity 
of the data could be increased by modifying the experimental 
method to: 1) decrease the influence of the many physio-
chemical factors which combine to influence the rates of 
drug absorption and excretion, and 2 ) increase the statis -
tical significance of the data obtained. 
( 
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VI. APPENDIX 
Determination of the Specific Surface of the Sulfadiazine 
Powder Used in the Preparation of Implanted Disks and Suspension 
The specific surface, (S ), the surface area per unit 
w 
weight of a substance, was determined for the drug grade 
sulfadiazine powder by micrometric analysis . Gross photo-
microscopic observation of the 20% aqueous suspension of the 
powder revealed uniformly suspended needle-shaped crystals. 
Direct visual microscopic analysis of the dry powder in 
Cargille immersion oil revealed needle-shaped crystals 
uniform in size with an occasional large particle. One 
hundred particles were selected at random and their lengths 
and widths determined. It was assumed that the height of 
each crystal was equal to its width . The powder density 
3 
was estimated by pycnome ter to be 1.43 gm/cm A summary of 
the properties of the sulf adiazine powder based upon the 
analysis of 100 randomly selected particles is as follows: 
· 1 1 h 1.086 X l0- 3cm Average partic e engt 
Average particle width 
Average particle height 
Density 
Particle volume 
Weight per particle 
Particles per gram 
Surf ace area per particle 
Surface area per gram powder 
Surf ace area per milligram of 
powder 
3 . 655 X l0- 4cm 
3.655 X l0-4cm 
3 1.43 gm/cm 
1. 4 5 1 X 10 - l O cm 3 
2 . 076 X 10-lOgm 
4.817 x 10 9 
1.8546 X l0 - 6cm2 
2 8933 cm /gm 
2 8.933 cm /mg 
r ( 
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